Sign in

Yoni Freedhoff

@yonifreedhoff.bsky.social
3.2K followers 191 following 211 posts

Associate Professor of Family Medicine @UOttawa/Exclusively obesity medicine since 2004/Bylines spanning from The Lancet to the NYTs/הנני

PostsRepliesMedia
Yoni Freedhoff @yonifreedhoff.bsky.social · 23/09/2026
Why the moral panic around treatment? What makes obesity different from all chronic noncommunicable disease that we readily treat in children to prevent future possible harms despite those conditions also not conferring immediate risks? www.medscape.com/viewarticle/...
medscape.com
Will Treating Kids' Obesity Trigger a New Moral Panic?
STEP Young just delivered the most effective childhood obesity treatment to date. Some critics already have their objections ready — even before the data are peer reviewed.
121
Yoni Freedhoff @yonifreedhoff.bsky.social · 23/09/2026
My latest for @medscape.com discusses the use of GLP1 in children with obesity and how some have decided that even if it works, it's bad. It's a remarkable position given the challenges and risks obesity confers to children's qualities of life and health given the drug's efficacy /1
120
Yoni Freedhoff @yonifreedhoff.bsky.social · 05/09/2026
Given ancillary benefits, have considered taking myself. Haven't yet, but a few more proven benefits and maybe I will
110
Yoni Freedhoff @yonifreedhoff.bsky.social · 04/09/2026
marked decrease in weight stigma as a whole and may even one day be replaced by the stigma of, "why isn't that person taking a GLP1"?. Full piece here www.medscape.com/viewarticle/...
medscape.com
Not an ‘Easy Way Out’: Rethinking GLP-1 Stigma
People choosing to take GLP-1s are being accused of taking a shortcut to weight loss, Dr Yoni Freedhoff argues that this stigma may fade as obesity gains recognition as a chronic disease.
181
Yoni Freedhoff @yonifreedhoff.bsky.social · 04/09/2026
A two-fer this week from me on @Medscape. My latest looks at the rise of stigma vs. the use of GLP1s and the perception that they are a "quick-fix". While that stigma definitely exists, rather than worsening over time, I'm betting the rise of GLP1 use will herald /1
161
Yoni Freedhoff @yonifreedhoff.bsky.social · 02/09/2026
My latest for @medscape.com . What if teen exposure to GLP1 related weight TikTok content is healthier than teen exposure to pre-GLP1 extreme & nonsensical dieting content? Sure would be nice to have some actual evidence, but my bet is, current stuff is less harmful. www.medscape.com/viewarticle/...
medscape.com
Is GLP-1 Social Media Content Really Harming Teens?
A viral report claims GLP-1 social media content is fueling teen eating disorders. Dr Yoni Freedhoff checked the literature and found that the data tell a different story.
030
Yoni Freedhoff @yonifreedhoff.bsky.social · 13/08/2026
and where physician counselling and support of same need not be so complicated. Perfect is the enemy of good. www.medscape.com/viewarticle/...
medscape.com
Overcomplicated GLP-1 Guidelines May Discourage Prescribing
A new GLP-1 consensus guideline pushes an idealized, interprofessional model—when a bare-bones standard could empower more clinicians to prescribe safely.
030
Yoni Freedhoff @yonifreedhoff.bsky.social · 13/08/2026
A recent Lancet published consensus statement chose the idealized route and I can't help but think if anything it'll do more to gatekeep, slow and even prevent the prescription of a class of medication that provides tremendous benefits /2
130
Yoni Freedhoff @yonifreedhoff.bsky.social · 13/08/2026
My latest for @medscape.com asks if it's wise to publish idealized guidelines for the use of GLP-1 meds rather than basic guidelines with an explanation covering what a more idealized prescription support program would look like? /1
130
Yoni Freedhoff @yonifreedhoff.bsky.social · 06/08/2026
That said, the impact of behavioural interventions layered on top of medications? That's an area ripe for research www.medscape.com/viewarticle/...
medscape.com
Ethical Failings in Behavioral Weight-Loss Interventions
Is it ethical to continue studying behavioral interventions alone for weight loss in the era of GLP-1s?
070
Yoni Freedhoff @yonifreedhoff.bsky.social · 06/08/2026
Behavioral-only interventions are intensive, nonscalable efforts leading to modest. not fully durable losses where no one diet or approach has demonstrable clinically meaningful superiority over another, and meanwhile we have incredibly effective therapeutics available /2
150
Yoni Freedhoff @yonifreedhoff.bsky.social · 06/08/2026
My latest for @null where I ask what are the ethics of conducting or publishing research on behavior-only weight-loss interventions for patients with obesity when we’ve had dozens of years of research that have come to the same basic conclusions /1
270
Yoni Freedhoff @yonifreedhoff.bsky.social · 05/08/2026
Decided I'm going to write an add-on for my book for the GLP1 era. Just as with dieting, so much misinformation around GLP1s and this addition very much inline with book's overarching aim to mythbust and to make ending traumatic dieting that much more doable. Hope to have available by January
1140
Yoni Freedhoff @yonifreedhoff.bsky.social · 06/07/2026
Had a nice chat with @caitlinschiller about my now vintage book The Diet Fix. Book holds up imo, but needs a chapter on permission to use GLP1s and mythbusting around them. The title btw wasn't my choice. Mine was, "A Prescription for Chocolate: The End of Traumatic Dieting". Can have a listen here:
simplify-show.beehiiv.com
Eat chocolate and enjoy life: a practical diet framework
Dr. Yoni Freedhoff on what having a "best weight" actually means
3131
Yoni Freedhoff @yonifreedhoff.bsky.social · 17/06/2026
Remarkable
000
Yoni Freedhoff @yonifreedhoff.bsky.social · 16/06/2026
Probably next year in the US, which means 2-3 more years here.
020
Yoni Freedhoff @yonifreedhoff.bsky.social · 16/06/2026
A shame because I think it would have suited CMAJ and would have been valuable to its audience of Canadian physicians. Bottom line here - coverage is a no-brainer medically but the challenge is cost,but here too, with generics, the times are a changing www.medscape.com/viewarticle/...
medscape.com
Even Physicians’ Insurance Plans Don’t Cover GLP-1s for Obesity
Many health insurance companies don’t even cover GLP-1s for physicians. Yoni Freedhoff, MD, asks why the lack of coverage.
160
Yoni Freedhoff @yonifreedhoff.bsky.social · 16/06/2026
Editors and Reviewer #1 were pretty much onboard. But Reviewer #2 - well as the many memes and jokes about him/her go - the MANY changes suggested/requested would have pushed this opinion piece into something it was never meant to be /2
130
Yoni Freedhoff @yonifreedhoff.bsky.social · 16/06/2026
My latest on @medscape.com on how even the insurance plans designed by and for physicians rarely cover GLP1 medications for obesity and the hypocrisy and short-sightedness therein. There's a backstory too. Had originally submitted as an opinion piece for @cmaj.ca /1
190
Yoni Freedhoff @yonifreedhoff.bsky.social · 12/06/2026
Anyhow, I thought it was worth taking the time to write about the state of where we are today with obesity. A remarkable place given not 15 years ago I was counselling MDs that their patients' weight maintenance represented laudable success www.medscape.com/viewarticle/...
medscape.com
Obesity Is Finally a Choice, Just Not Like You Imagined
Nobody chooses to live with obesity, and previous efforts show that lifestyle changes aren’t necessarily the solution. Yoni Freedhoff, MD, explains why obesity is now a choice.
040
Yoni Freedhoff @yonifreedhoff.bsky.social · 12/06/2026
With the next generation of medications, that number would likely near 95%. But the catch is the accessibility and affordability piece. Happily, the affordability problem is rapidly improving whereby at least here in Canada, GLP1 costs are down to $100-200/month (for semaglutide)
240
Yoni Freedhoff @yonifreedhoff.bsky.social · 12/06/2026
My latest in @medscape.com on how obesity is finally, truly, a choice. But no, not the choice of trying harder, but rather of therapeutics, where even our current generation of medications and surgeries, if accessible and affordable to all, would push 90% of obesity into remission
151
Yoni Freedhoff @yonifreedhoff.bsky.social · 07/05/2026
So low!! Are there any labs that also strive to measure viral shedding to rule out possibility that changes have occured to same as strains have evolved?
100
Yoni Freedhoff @yonifreedhoff.bsky.social · 01/05/2026
My latest in @medscape.com: Seems that one by one the fear mongered risks about GLP1s get disproven. No increased suicide risk, no thyroid cancer risk, no blindness risk. But the loudest these days is muscle loss risk. Well guess what? No meaningful risk there either www.medscape.com/viewarticle/...
medscape.com
No Need to Worry About GLP-1-Induced Muscle Loss
Recent headlines have alarmingly stated dramatic muscle loss for patients on GLP-1s. Yoni Freedhoff, MD, explains why this is a manufactured controversy.
192
Yoni Freedhoff @yonifreedhoff.bsky.social · 23/03/2026
My latest for @medscape.com covers how the diet era is already dead, it just doesn't know it yet and why that's glorious www.medscape.com/viewarticle/...
medscape.com
The Bell Tolls for the Diet Era
Does the new generation of weight-loss drugs mark the end for weight-loss diet researchers, fat-acceptance entrepreneurs, and others? Yoni Freedhoff, MD, thinks it does.
180
Yoni Freedhoff @yonifreedhoff.bsky.social · 04/02/2026
My latest on @medscape.com covers some thoughts on the new American Dietary Guidelines and why they actually matter a great deal even if it's true that virtually no one consciously follows or cares about them www.medscape.com/viewarticle/...
medscape.com
Why Diet Guidelines Matter Even if Zero People Follow Them
0102
Yoni Freedhoff @yonifreedhoff.bsky.social · 24/12/2025
My latest on @Medscape - can you successfully sue your employer for GLP1 coverage? Though plaintiffs have already tried and failed, two new developments have made a new potential case much, much stronger www.medscape.com/viewarticle/...
medscape.com
Two New Developments May Help Future Plaintiffs Compel GLP-1 Coverage
Two recent developments may potentially increase GLP-1 coverage for more patients with obesity. The lack of coverage may be another failure of recognizing obesity as a chronic disease.
051
Reposted by Yoni Freedhoff
Jeffrey B. Benyacar @drjeffreyb.bsky.social · 18/12/2025
I double checked this and it's true. You teach clinicians that naming identity matters and that erasure is harm, yet when Jews are targeted you suddenly forget that lesson, which is not neutrality but a failure of your own stated ethics. 🛟 #medtwitter
141
Yoni Freedhoff @yonifreedhoff.bsky.social · 10/12/2025
If you'd like to read further, here's the full article link: medscape.com/viewarticle/...
medscape.com
Black Coffee and Cancer Hype Unsubstantiated
Recent claims that black coffee decreases cancer or whole-body vibration melts fat are increasingly being published. These attention-grabbing studies are misleading and do the public a disservice.
282
Yoni Freedhoff @yonifreedhoff.bsky.social · 10/12/2025
I appreciate that for both authors and journals it's a publish or perish world but the problem is, the media amplification of these sorts of studies, especially the food ones, contributes to nutritional and scientific illiteracy and hence publication is not free from harm
161
Yoni Freedhoff @yonifreedhoff.bsky.social · 10/12/2025
The tl;dr is that single food studies (especially p-hacked ones like this) can't really make conclusions and that we shouldn't need a study to tell us standing on a vibrating plate doesn't lead to weight loss
141
Yoni Freedhoff @yonifreedhoff.bsky.social · 10/12/2025
My latest in @medscape.com covers two recently published studies. The first claimed black coffee would prevent cancer. The second, and hold onto your hats, that whole body vibration treatments don't help with weight loss
1101
Yoni Freedhoff @yonifreedhoff.bsky.social · 15/11/2025
My latest on @medscape.com on how declining obesity rates are now almost certainly attributable to GLP-1 medications, but how new guidelines meant to be wiser than BMI in its diagnosis are apparently diagnosing 70% of the population with obesity www.medscape.com/viewarticle/...
medscape.com
We’re Curing Obesity, But Far More People Apparently Have It
Recent reports show a decrease in obesity rates; however, a new proposed definition predicts a surge of people with obesity.
3113
Yoni Freedhoff @yonifreedhoff.bsky.social · 31/10/2025
If you prefer a podcast link, here's you go: podcasts.apple.com/ca/podcast/d...
podcasts.apple.com
Doctors Speak Out: The Reality of Antisemitism in Medicine
Podcast Episode · Breaking the Narrative · 2025-10-30 · 59m
021
Yoni Freedhoff @yonifreedhoff.bsky.social · 31/10/2025
If regulators fail to uphold their statutory duty to act in the public interest, they may be inviting legal challenge — and moral reckoning. The question is: who will test that duty first?
210
Yoni Freedhoff @yonifreedhoff.bsky.social · 31/10/2025
This isn’t just theoretical. Inaction signals to racialized patients that their safety and dignity are negotiable — and to the public that accountability in medicine is optional.
100
Yoni Freedhoff @yonifreedhoff.bsky.social · 31/10/2025
Courts have found regulators can be liable for negligent oversight when foreseeable harm occurs. Ignoring racism that deters or harms patients might meet that threshold.
100
Yoni Freedhoff @yonifreedhoff.bsky.social · 31/10/2025
As statutory bodies exercising public authority, medical regulators could also face Charter scrutiny. Inaction that allows racist conduct to persist may violate patients’ equality rights under Section 15.
100
Yoni Freedhoff @yonifreedhoff.bsky.social · 31/10/2025
If regulators ignore such conduct, they may be breaching not only their own legislation but also the Ontario Human Rights Code, which protects equal access to services, including healthcare.
100
Yoni Freedhoff @yonifreedhoff.bsky.social · 31/10/2025
Racist public conduct isn’t “private speech.” It signals bias that can affect care. Under the Medicine Act, such behaviour could constitute “disgraceful, dishonourable, or unprofessional conduct.”
100
Yoni Freedhoff @yonifreedhoff.bsky.social · 31/10/2025
Regulators like the CPSO have a legal duty under the Regulated Health Professions Act to “serve and protect the public interest.” Turning a blind eye to racism is hard to square with that mandate.
100
Yoni Freedhoff @yonifreedhoff.bsky.social · 31/10/2025
Medical regulators exist to protect the public. In Canada and the UK, some have failed to act when physicians publicly spread racist messages. That inaction erodes confidence in both the profession and its regulators.
100
Yoni Freedhoff @yonifreedhoff.bsky.social · 31/10/2025
When physicians post racist content, patients who belong to targeted groups can reasonably fear danger, denial of care, or substandard treatment. That fear alone undermines trust in healthcare.
100
Yoni Freedhoff @yonifreedhoff.bsky.social · 31/10/2025
Yesterday, @standwithus.bsky.social Canada posted the podcast that Montreal's Dr. Lior Bibas and I recorded about antisemitism and antizionism in medicine in Canada. Among the topics, what legal liability has the CPSO exposed themselves to by not acting? www.youtube.com/watch?v=StMK...
youtube.com
Doctors Speak Out: The Reality of Antisemitism in Medicine
YouTube video by StandWithUs Canada
111
Yoni Freedhoff @yonifreedhoff.bsky.social · 08/10/2025
My review of @juliabelluz.bsky.social and @kevinh-phd.bsky.social's new book Food Intelligence finally published on @medscape.com. tl;dr? If you're looking for a detailing of our current understanding of the science of food, eating, and metabolism, this one's for you www.medscape.com/viewarticle/...
medscape.com
What We Know and Don’t Know About Nutrition and Health
Yoni Freedhoff, MD, reviews the new book 'Food Intelligence,' which details the impact of food on nutrition, biochemistry, metabolism, and health.
02810
Yoni Freedhoff @yonifreedhoff.bsky.social · 21/08/2025
Link to full piece (registration is, as always, free) medscape.com/viewarticle/...
medscape.com
GLP-1s Don’t Increase Suicide Risk
Many patients inquire about the risk of suicidal ideation with GLP-1s, writes Yoni Freedhoff, MD. Rather than increasing the risk, he has found they actually decrease it.
050
Yoni Freedhoff @yonifreedhoff.bsky.social · 21/08/2025
whereby the studies receiving the most media attention are those reporting literally negative (ie, adverse) outcomes. In contrast, more rigorous studies that challenge these negative findings, even if publicized, rarely achieve comparable societal penetration or awareness /3
140
Yoni Freedhoff @yonifreedhoff.bsky.social · 21/08/2025
Since then have you heard that no, GLP1 meds almost certainly don't increase the risk of suicide and might in fact contribute to improved mood? I'm betting that's less likely and the reason why is negative publication bias - media edition /2
130
Yoni Freedhoff @yonifreedhoff.bsky.social · 21/08/2025
My latest in @medscape.com on GLP1 meds and suicide: Did you hear GLP1 meds might increase the risk of suicide? I'd bet you did. It was all over the news consequent to just 3 case reports submitted by Iceland to the European Medicine Association who announced an investigation /1
2100
Reposted by Yoni Freedhoff
Tyson Graber @rnaguru.bsky.social · 04/07/2025
@yonifreedhoff.com Here are violin plots showing distribution of the ww signal in Ottawa by year and by VOC. "wwlast30d" represents signal sampled over past 30 days. A 5-year, continuous public health dataset unaffected by policy changes--unlike clinical indicators--is a beautiful thing.
2 plots showing distributions of ww signal by year and by VOC.
191